Evaluation of selective human MAO inhibitory activities of some novel pyrazoline derivatives


Salgin-Goksen U., Yabanoglu-Ciftci S. , ERCAN A. , Yelekci K., UÇAR G. , Gokhan-Kelekci N.

JOURNAL OF NEURAL TRANSMISSION, vol.120, no.6, pp.863-873, 2013 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 120 Issue: 6
  • Publication Date: 2013
  • Doi Number: 10.1007/s00702-013-0980-6
  • Title of Journal : JOURNAL OF NEURAL TRANSMISSION
  • Page Numbers: pp.863-873

Abstract

A series of 1-[2-((5-methyl/chloro)-2-benzoxazolinone-3-yl)acetyl]-3,5-diaryl-4,5-dihydro-1H-pyrazole derivatives were prepared by reacting 2-((5-methyl/chloro)-2-benzoxazolinone-3-yl)acetylhydrazine with appropriate chalcones. The chemical structures of all compounds were confirmed by elemental analyses, IR, H-1 NMR and ESI-MS. All the compounds were investigated for their ability to selectively inhibit monoamine oxidase (MAO) by in vitro tests. MAO activities of the compounds were compared with moclobemide and selegiline and all the compounds were found to inhibit human MAO-A selectively. The inhibition profile was found to be competitive and reversible for all compounds by in vitro tests. Among the compounds examined, compounds 5ae, 5af and 5ag were more selective than moclobemide, with respect to the K (i) values experimentally found. In addition, the compound 5bg showed MAO-A inhibitor activity as well as moclobemide. A series of experimentally tested compounds (5ae-5ch) were docked computationally to the active site of the MAO-A and MAO-B isoenzyme. The AUTODOCK 4.01 program was employed to perform automated molecular docking.